Investigation into Acadia Healthcare Company
Acadia Healthcare Company, Inc. (NASDAQ: ACHC), a prominent player in the psychiatric hospital sector in the United States, is facing serious scrutiny after recent revelations involving legal inquiries into its practices. Bleichmar Fonti & Auld LLP, a leading law firm, has initiated an investigation regarding potential violations of federal securities laws affecting investors.
Recent Developments and Stock Impact
The investigation follows alarming news that on September 27, 2024, Acadia revealed it has received subpoenas from the U.S. Attorney's Office in New York and is under investigation by the U.S. Securities and Exchange Commission (SEC). This inquiry is focused on various operational practices, including patient admissions, billing, and the length of hospital stays.
Allegations Against Acadia Healthcare
The scrutiny intensified after Acadia was found to have settled for $19.85 million, admitting in the process that from 2014 to 2017, it had submitted false claims for billing related to inpatient behavioral services which were, allegedly, not medically necessary. This included admitting patients who weren't eligible for treatment and improperly discharging those who were ready to leave.
Continued Concerns
A recent investigative report published by a major newspaper raised concerns that the troubling practices identified in the previous investigations may still be occurring. Such developments have understandably alarmed investors, leading to a sharp decline in the company’s stock price, which fell over 17% on the morning of September 27, 2024.
What Should Investors Do?
If you are an investor in Acadia Healthcare, it's crucial to stay informed and consider your options. Bleichmar Fonti & Auld LLP encourages affected shareholders to submit their details, as they may have legal grounds to pursue compensation. Representations are provided on a contingency fee basis, meaning no upfront payment for plaintiffs.
Why Choose Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is highly regarded for its specialization in securities class actions and shareholder litigation. With a track record of successful recoveries, including significant settlements from companies such as Tesla and Teva Pharmaceuticals, they are well-equipped to handle complex legal challenges faced by investors.
Contact Information
For those thinking about pursuing legal action, you can contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
Frequently Asked Questions
What is the nature of the investigation into Acadia Healthcare?
The investigation focuses on potential violations of federal securities laws related to patient admissions and billing practices.
Why did Acadia Healthcare's stock price drop?
The stock price fell sharply following news of legal subpoenas related to improper billing practices and allegations of submitting false claims to Medicare and Medicaid.
What legal options do Acadia investors have?
Investors may have grounds for legal action due to the stock's decline and should consider contacting Bleichmar Fonti & Auld LLP for potential representation.
Is there any cost for representation?
All representation by Bleichmar Fonti & Auld LLP is on a contingency fee basis, meaning there is no upfront cost for plaintiffs.
How can I get in touch with the law firm?
You can reach out by emailing Ross Shikowitz at ross@bfalaw.com or calling 212-789-3619.
